CPC
HRTX icon

Congress Park Capital’s Heron Therapeutics HRTX Stock Holding History

Congress Park Capital’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$861K Sell
2,016,447
-2,016,290
-50% -$1.62M 0.23% 70
2026
Q1 		$3.23M Buy
4,032,737
+965,262
+31% +$1.12M 0.99% 28
2025
Q4 		$3.99M Buy
3,067,475
+177,318
+6% +$219K 1.19% 26
2025
Q3 		$3.64M Buy
2,890,157
+621,908
+27% +$986K 1.13% 26
2025
Q2 		$4.7M Buy
2,268,249
+232,632
+11% +$475K 1.54% 22
2025
Q1 		$4.48M Sell
2,035,617
-419,878
-17% -$815K 1.7% 18
2024
Q4 		$3.76M Buy
2,455,495
+477,417
+24% +$774K 1.36% 23
2024
Q3 		$3.94M Buy
1,978,078
+399,577
+25% +$954K 1.46% 21
2024
Q2 		$5.52M Sell
1,578,501
-66,284
-4% -$204K 2.22% 13
2024
Q1 		$4.56M Sell
1,644,785
-153,865
-9% -$387K 2.02% 14
2023
Q4 		$3.06M Buy
1,798,650
+1,209,500
+205% +$1.33M 1.49% 19
2023
Q3 		$607K Buy
589,150
+77,900
+15% +$111K 0.32% 69
2023
Q2 		$593K Buy
511,250
+190,590
+59% +$340K 0.3% 74
2023
Q1 		$484K Buy
320,660
+60,550
+23% +$152K 0.25% 79
2022
Q4 		$650K Buy
260,110
+89,350
+52% +$288K 0.38% 65
2022
Q3 		$721K Buy
170,760
+10,500
+7% +$41.1K 0.42% 53
2022
Q2 		$447K Buy
160,260
+32,512
+25% +$131K 0.27% 81
2022
Q1 		$731K Buy
127,748
+38,131
+43% +$279K 0.37% 63
2021
Q4 		$818K Sell
89,617
-30,110
-25% -$307K 0.4% 58
2021
Q3 		$1.28M Sell
119,727
-76,760
-39% -$935K 0.65% 44
2021
Q2 		$3.05M Buy
196,487
+3,840
+2% +$61.1K 1.53% 16
2021
Q1 		$3.12M Sell
192,647
-4,970
-3% -$88.6K 1.75% 15
2020
Q4 		$4.18M Sell
197,617
-7,232
-4% -$126K 2.48% 13
2020
Q3 		$3.04M Buy
204,849
+4,485
+2% +$70K 1.88% 18
2020
Q2 		$2.95M Buy
200,364
+89,319
+80% +$1.47M 2.26% 15
2020
Q1 		$1.3M Sell
111,045
-2,200
-2% -$41.4K 1.18% 22
2019
Q4 		$2.66M Buy
113,245
+1,980
+2% +$43.8K 1.96% 18
2019
Q3 		$2.06M Buy
111,265
+1,600
+1% +$29.4K 1.73% 19
2019
Q2 		$1.95M Buy
109,665
+58,790
+116% +$1.17M 1.54% 18
2019
Q1 		$1.24M Buy
50,875
+4,300
+9% +$113K 1.07% 30
2018
Q4 		$1.21M Buy
46,575
+11,350
+32% +$312K 1.33% 24
2018
Q3 		$1.11M Sell
35,225
-100
-0.3% -$3.73K 1% 31
2018
Q2 		$1.37M Sell
35,325
-3,900
-10% -$124K 1.32% 23
2018
Q1 		$1.08M Sell
39,225
-7,400
-16% -$168K 1.11% 27
2017
Q4 		$844K Buy
+46,625
New +$760K 0.85% 40

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Congress Park Capital's HRTX Position: Q2 2026 in Review

Congress Park Capital reduced its Heron Therapeutics (HRTX) stake by 50% in Q2 2026, selling an estimated $1.62M and leaving 2,016,447 shares worth $861K. The position accounts for 0.23% of the portfolio, ranked #70.

Congress Park Capital first reported a position in HRTX in Q4 2017 and has held it in 35 quarters since. The position peaked at $5.52M in Q2 2024. 162 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • Congress Park Capital held 2,016,447 shares of Heron Therapeutics worth $861K as of Q2 2026.
  • Congress Park Capital sold 2,016,290 Heron Therapeutics shares in Q2 2026, an estimated $1.62M.
  • Heron Therapeutics made up 0.23% of Congress Park Capital's portfolio in Q2 2026, its #70 holding.
  • Congress Park Capital first reported a position in Heron Therapeutics in Q4 2017 and has held it in 35 quarters since.
  • Congress Park Capital's Heron Therapeutics position peaked at $5.52M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Congress Park Capital's 13F filing for Q2 2026, filed 14 Jul 2026.